Evidence mapPaperPMID 36364723Full record

SynthesisNutrients2022

The Effect of Walnut Intake on Lipids: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Saeed Mastour Alshahrani, Reham M Mashat, Diaa Almutairi, Alaa Mathkour, Sahar Saad Alqahtani, Amirah Alasmari, Abdullah Hassan Alzahrani, Reem Ayed, Mohammed Yahya Asiri, Alsanussi Elsherif and 1 more

Abstract readMeta-AnalysisSystematic Review
In one paragraph

Synthesis in Nutrients, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 2 pooled it
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Review
  6. Deciphering the pharmacological mechanisms of salidroside in cervical cancer by combining network pharmacology, molecular docking, and in vitro studies.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2025
    Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Saeed Mastour AlshahraniDepartment of Public Health, College of Applied Medical Sciences, King Khalid University, Khamis Mushait 62529, Saudi Arabia.ORCID 0000-0003-2714-7785
Reham M MashatNutrition and Food Sciences, College of Home Economics, King Khalid University, Abha 62529, Saudi Arabia.ORCID 0000-0003-1436-1459
Diaa AlmutairiPrince Sultan Military College of Health Sciences, Dhahran 34247, Saudi Arabia.
Alaa MathkourMinistry of Health, Riyadh 12613, Saudi Arabia.ORCID 0000-0002-4102-7061
Sahar Saad AlqahtaniDepartment of Public Health, College of Applied Medical Sciences, King Khalid University, Khamis Mushait 62529, Saudi Arabia.
Amirah AlasmariMinistry of Health, Riyadh 12613, Saudi Arabia.ORCID 0000-0002-4932-3519
Abdullah Hassan AlzahraniMinistry of Health, Riyadh 12613, Saudi Arabia.
Reem AyedPublic Health Authority, Riyadh 13351, Saudi Arabia.
Mohammed Yahya AsiriMinistry of Health, Riyadh 12613, Saudi Arabia.
Alsanussi ElsherifDepartment of Family and Community Medicine, Faculty of Medicine, University of Benghazi, Benghazi 1308, Libya.
Abdullah AlsabaaniDepartment of Family and Community Medicine, College of Medicine, King Khalid University, Abha 62529, Saudi Arabia.ORCID 0000-0003-2352-8249

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cardiovascular diseases (CVD) are the leading causes of death worldwide. Dyslipidemia is a cardiometabolic risk factor of CVD, yet it can be modifiable. Walnuts have been suggested as a dietary intervention to improve the lipid profile. Therefore, we reviewed the literature to assess the evidence linking walnut intake to the improvement of blood lipids, including total cholesterol (TC), low-density lipoprotein (LDL-C) cholesterol, high-density lipoprotein (HDL-C) cholesterol, and triglycerides (TG). PubMed and Embase databases were searched from 2010 up to March 2022. We limited our search to randomized controlled trials conducted on humans and published in English during the specified period. Cochrane's risk of bias tool for interventional studies was used. A random-effects model was used for the meta-analysis, and weighted mean differences were obtained (WMD) Thirteen trials from the U.S., Europe, and Asia were included. Walnut intake was associated with significant reductions in TC (WMD: -8.58 mg/dL), LDL-C (WMD: -5.68 mg/dL), and TG (WMD: -10.94 mg/dL). Walnut consumption was not associated with HDL-C. Subgroup analysis showed that overweight/obese and those with comorbidities had more lipid improvement. A longer trial duration did result in further improvements. However, our results may be prone to bias due to extraneous confounding factors. Additionally, levels of heterogeneity were considerable for some outcomes of interest. Results from this meta-analysis provide evidence for the health benefits of walnuts on blood lipids. Walnuts possibly reduce the risk of CVD; thus, they can be successfully added to a dietary pattern to enhance health benefits.

Indexed as

Cardiovascular DiseasesJuglansCholesterolCholesterol, HDLCholesterol, LDLHumansLipidsRandomized Controlled Trials as TopicTriglyceridesCholesterolCholesterol, HDLCholesterol, LDLLipidsTriglyceridesdyslipidemialow density lipoprotein cholesterol (LDL-C)meta-analysisrandomized controlled trialstotal cholesterol (TC)triglyceride (TG)walnuts

Identifiers

PMID36364723
PMCPMC9655834

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.